Intelligent Investor

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.125 0.01 (7.41%)

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$52 Positive DEP irinotecan clinical results presentation 13 Sep 2023 9:46AM $0.130 $0.125 $0.130 fallen by 3.85%
$52 Change in substantial holding 12 Sep 2023 5:10PM $0.130 $0.125 $0.130 fallen by 3.85%
$52 Company Secretary Appointment/Resignation 28 Aug 2023 9:17AM $0.140 $0.125 $0.130 fallen by 10.71%
$52 Corporate Governance Statement 25 Aug 2023 4:46PM $0.140 $0.125 $0.130 fallen by 10.71%
$52 Appendix 4G - Corporate Governance Statement 24 Aug 2023 9:38AM $0.145 $0.125 $0.130 fallen by 13.79%
$52 App 4E/Annual Report to shareholders 24 Aug 2023 9:37AM $0.145 $0.125 $0.130 fallen by 13.79%
$52 Change in substantial holding 17 Aug 2023 6:09PM $0.160 $0.125 $0.130 fallen by 21.88%
$52 Change in substantial holding 17 Aug 2023 4:20PM $0.160 $0.125 $0.130 fallen by 21.88%
$52 Change in substantial holding 15 Aug 2023 4:42PM $0.170 $0.125 $0.130 fallen by 26.47%
$52 SPL to receive $6.5M from Mundipharma and VivaGel BV rights 14 Aug 2023 8:15AM $0.150 $0.125 $0.130 fallen by 16.67%
$52 Change in substantial holding 2 Aug 2023 8:26AM $0.195 $0.125 $0.130 fallen by 35.90%
$52 Partnered Program Update 31 Jul 2023 10:07AM $0.325 $0.125 $0.130 fallen by 61.54%
$52 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2023 9:53AM $0.325 $0.125 $0.130 fallen by 61.54%
$52 Trading Halt 28 Jul 2023 9:51AM $0.325 $0.125 $0.130 fallen by 61.54%
$52 Pause in Trading 28 Jul 2023 9:45AM $0.325 $0.125 $0.130 fallen by 61.54%
$52 Starpharma partners with UQ to advance DEP radio pipeline 26 Jul 2023 9:30AM $0.360 $0.125 $0.130 fallen by 65.28%
$52 DEP HER2-radiodiagnostic shows imaging benefits 21 Jul 2023 9:02AM $0.370 $0.125 $0.130 fallen by 66.22%
$52 Notification of cessation of securities - SPL 7 Jul 2023 2:13PM $0.350 $0.125 $0.130 fallen by 64.29%
$52 Clinical Trial Update 27 Jun 2023 9:57AM $0.325 $0.125 $0.130 fallen by 61.54%
$52 Life Sciences Investor Forum Presentation 23 Jun 2023 10:42AM $0.355 $0.125 $0.130 fallen by 64.79%
$52 Starpharma to present at Life Sciences Investor Forum 22 Jun 2023 12:48PM $0.350 $0.125 $0.130 fallen by 64.29%
$52 AZD0466 Clinical Data Presented by AstraZeneca EHA Congress 14 Jun 2023 10:36AM $0.380 $0.125 $0.130 fallen by 67.11%
$52 Starpharma CEO to retire in 2024 9 Jun 2023 9:32AM $0.370 $0.125 $0.130 fallen by 66.22%
$52 VIRALEZE Nasal Spray Approved in Malaysia 5 Jun 2023 9:45AM $0.390 $0.125 $0.130 fallen by 67.95%
$52 Application for quotation of securities - SPL 5 May 2023 5:04PM $0.450 $0.125 $0.130 fallen by 72.22%

51 - 75 of 756 results

Page 3 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.